These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 29364523)

  • 1. Population Pharmacokinetics of the TNF-α and IL-17A Dual-Variable Domain Antibody ABT-122 in Healthy Volunteers and Subjects With Psoriatic or Rheumatoid Arthritis: Analysis of Phase 1 and 2 Clinical Trials.
    Khatri A; Othman AA
    J Clin Pharmacol; 2018 Jun; 58(6):803-813. PubMed ID: 29364523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of ABT-122, a TNF-α- and IL-17A-Targeted Dual-Variable Domain Immunoglobulin, in Healthy Subjects and Patients with Rheumatoid Arthritis: Results from Three Phase I Trials.
    Khatri A; Goss S; Jiang P; Mansikka H; Othman AA
    Clin Pharmacokinet; 2018 May; 57(5):613-623. PubMed ID: 28744796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exposure-response analyses demonstrate no evidence of interleukin 17A contribution to efficacy of ABT-122 in rheumatoid or psoriatic arthritis.
    Khatri A; Klünder B; Peloso PM; Othman AA
    Rheumatology (Oxford); 2019 Feb; 58(2):352-360. PubMed ID: 30376130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ABT-122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukin-17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate: A Randomized, Double-Blind Study.
    Genovese MC; Weinblatt ME; Aelion JA; Mansikka HT; Peloso PM; Chen K; Li Y; Othman AA; Khatri A; Khan NS; Padley RJ
    Arthritis Rheumatol; 2018 Nov; 70(11):1710-1720. PubMed ID: 29855172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II Study of ABT-122, a Tumor Necrosis Factor- and Interleukin-17A-Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate.
    Mease PJ; Genovese MC; Weinblatt ME; Peloso PM; Chen K; Othman AA; Li Y; Mansikka HT; Khatri A; Wishart N; Liu J
    Arthritis Rheumatol; 2018 Nov; 70(11):1778-1789. PubMed ID: 29855175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis.
    Genovese MC; Weinblatt ME; Mease PJ; Aelion JA; Peloso PM; Chen K; Li Y; Liu J; Othman AA; Khatri A; Mansikka HT; Leszczynski P
    Rheumatology (Oxford); 2018 Nov; 57(11):1972-1981. PubMed ID: 30032191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, Tolerability, and Pharmacodynamics of ABT-122, a Tumor Necrosis Factor- and Interleukin-17-Targeted Dual Variable Domain Immunoglobulin, in Patients With Rheumatoid Arthritis.
    Fleischmann RM; Wagner F; Kivitz AJ; Mansikka HT; Khan N; Othman AA; Khatri A; Hong F; Jiang P; Ruzek M; Padley RJ
    Arthritis Rheumatol; 2017 Dec; 69(12):2283-2291. PubMed ID: 28941216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
    Zhou H; Mayer PR; Wajdula J; Fatenejad S
    J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, Safety, and Tolerability of the Dual Inhibitor of Tumor Necrosis Factor-α and Interleukin 17A, ABBV-257, in Healthy Volunteers and Patients With Rheumatoid Arthritis.
    Othman AA; Khatri A; Loebbert R; Peloso PM
    Clin Pharmacol Drug Dev; 2019 May; 8(4):492-502. PubMed ID: 30156758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I-III Clinical Trials.
    Klünder B; Mittapalli RK; Mohamed MF; Friedel A; Noertersheuser P; Othman AA
    Clin Pharmacokinet; 2019 Aug; 58(8):1045-1058. PubMed ID: 30945116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
    Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
    Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis.
    Mohamed MF; Camp HS; Jiang P; Padley RJ; Asatryan A; Othman AA
    Clin Pharmacokinet; 2016 Dec; 55(12):1547-1558. PubMed ID: 27272171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials.
    Klünder B; Mohamed MF; Othman AA
    Clin Pharmacokinet; 2018 Aug; 57(8):977-988. PubMed ID: 29076110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity.
    Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
    Arthritis Res Ther; 2016 Jul; 18(1):160. PubMed ID: 27391315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy.
    Kremer JM; Emery P; Camp HS; Friedman A; Wang L; Othman AA; Khan N; Pangan AL; Jungerwirth S; Keystone EC
    Arthritis Rheumatol; 2016 Dec; 68(12):2867-2877. PubMed ID: 27389975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of interleukin-17A inhibitor in Japanese patients with psoriatic arthritis compared with tumor necrosis factor-alpha inhibitor.
    Izumiyama T; Mori Y; Oizumi I; Hamada S; Kurishima H; Terui H; Omori-Shimada R; Yamasaki K; Itoi E
    J Orthop Surg (Hong Kong); 2021; 29(2):23094990211012286. PubMed ID: 33938296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis.
    Xu Z; Vu T; Lee H; Hu C; Ling J; Yan H; Baker D; Beutler A; Pendley C; Wagner C; Davis HM; Zhou H
    J Clin Pharmacol; 2009 Sep; 49(9):1056-70. PubMed ID: 19617465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors.
    Genovese MC; Greenwald M; Cho CS; Berman A; Jin L; Cameron GS; Benichou O; Xie L; Braun D; Berclaz PY; Banerjee S
    Arthritis Rheumatol; 2014 Jul; 66(7):1693-704. PubMed ID: 24623718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and Tolerability of a Dual Variable Domain Immunoglobulin ABT-981 Against IL-1α and IL-1β in Healthy Subjects and Patients With Osteoarthritis of the Knee.
    Kosloski MP; Goss S; Wang SX; Liu J; Loebbert R; Medema JK; Liu W; Dutta S
    J Clin Pharmacol; 2016 Dec; 56(12):1582-1590. PubMed ID: 27150261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis.
    Culy CR; Keating GM
    Drugs; 2002; 62(17):2493-537. PubMed ID: 12421111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.